“Is curing patients a sustainable business model?”

No financial incentive in creating definite cures

#Health

Tue, Apr 17th, 2018 11:00 by capnasty NEWS

According to CNBC, a report by a Goldman Sachs analysts notes that gene therapy treatment could be "bad for business in the long run."

"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."

  441

 

You may also be interested in:

Fecal Transplants
Neutral, Unbranded Cigaratte Packages May Encourage Smokers to Quit
7min: Timer to Help You Perform the Scientific Seven Minute Workout
Whole, Functional Organ Grown from Scratch
Getting New Breasts from a Discount Hospital in Thailand